EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Thoracic radiotherapy timing and prognostic factors in elderly patients with limited‐stage small cell lung cancer

Huan Zhao, Yue Qi, Lanfang Zhang, Meng Xing, Fujun Yang iD

Precision Radiation Oncology · 2024-03 · 8 (1) · 14-21

DOI: 10.1002/pro6.1223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Precision Radiation Oncology, online erschienen am 14.03.2024. Verfasst von Huan Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Binzhou Medical University Yantai Shandong China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study assessed the outcomes of elderly patients with limited‐stage small cell lung cancer (LS‐SCLC), which may be linked to the timing of thoracic radiotherapy (TRT) following chemotherapy.

Methods

Elderly patients ( n = 78) with LS‐SCLC were divided into three groups depending on the timing of radiotherapy. The patients in the TRT group were stratified into early (TRT after 1–2 cycles of chemotherapy, n = 29), medium‐term (TRT after 3–4 cycles of chemotherapy, n = 33), and late (TRT after 5–6 cycles of chemotherapy, n = 16) TRT groups. The overall survival (OS) and progression‐free survival (PFS) were assessed and compared.

Results

The medium‐term TRT group demonstrated significantly longer mPFS (20.12 months) and better mOS (35.97 months) than those in the other groups (PFS: P = 0.021;OS: P = 0.035). A pairwise comparison of the three groups revealed that those who received medium‐term TRT exhibited significantly improved PFS than the early (mPFS: 20.12 vs. 10.36 mouths, P = 0.018) and late (mPFS: 20.12 vs. 9.17 months, P = 0.016) TRT. The medium‐term TRT group demonstrated significantly improved OS than the early TRT (mOS: 35.97 vs. 25.22 months, P = 0.007) but not in comparison with the late TRT (mOS: 35.97 vs. 21.63 months, P = 0.100).

Conclusion

In elderly patients with LS‐SCLC, the addition of TRT after 3–4 cycles of chemotherapy appears to be a viable and potentially beneficial treatment approach.

Schlagwörter

Stichwörter der Autor:innen

elderly patientsintensity modulated radiation therapylimited‐stage small cell lung cancerprognosisradiotherapy timingthoracic radiotherapy

Autor:innen und Institutionen

  • Binzhou Medical University Yantai Shandong China.
  • Key Laboratory of Precision Diagnosis and Treatment in Oncology of Weihai Department of Oncology Weihai Municipal Hospital Weihai Shandong China.

ORCID-Profile: Fujun Yang

Zitieren

APA

Zhao, H., Qi, Y., Zhang, L., Xing, M., & Yang, F. (2024). Thoracic radiotherapy timing and prognostic factors in elderly patients with limited‐stage small cell lung cancer. Precision Radiation Oncology, 8(1), 14-21. https://doi.org/10.1002/pro6.1223

Vancouver

Zhao H, Qi Y, Zhang L, Xing M, Yang F. Thoracic radiotherapy timing and prognostic factors in elderly patients with limited‐stage small cell lung cancer. Precision Radiation Oncology. 2024;8(1):14-21. doi:10.1002/pro6.1223

BibTeX
@article{Zhao2024,
  author = {Zhao, Huan and Qi, Yue and Zhang, Lanfang and Xing, Meng and Yang, Fujun},
  title = {Thoracic radiotherapy timing and prognostic factors in elderly patients with limited‐stage small cell lung cancer},
  journal = {Precision Radiation Oncology},
  year = {2024},
  volume = {8},
  number = {1},
  pages = {14--21},
  doi = {10.1002/pro6.1223}
}
Kostenlos starten →